BACKGROUND: Coronary artery stents are tiny tubular devices used to 'scaffold' vessels open during percutaneous transluminal coronary angioplasty (PTCA). @entity256 (re-narrowing) of vessels treated with stents is a problem; in order to reduce restenosis, stents that elute drugs over time are available. An earlier review reported limited benefit for these more expensive devices. There is a need to assess their clinical benefits now that longer term data are available. OBJECTIVES: To update the previously published review which aimed to assess the clinical effectiveness of routine stenting with drug-eluting compared with non-eluting coronary artery stents in adults with stable @entity951 or @entity1187 (including @entity583 and @entity1459 ). SEARCH METHODS: The Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 10, 2012 on The Cochrane Library), MEDLINE (OVID, 1946 to October week 4 2012) and EMBASE (OVID, 1980 to 2012 week 43) were searched. We carried out handsearching (electronic) up to May 2012. No language restrictions were applied. SELECTION CRITERIA: We included RCTs comparing DES with BMS used in conjunction with PTCA techniques in the review. @entity1 were adults with stable @entity951 or @entity1187 ( @entity1187 ). We considered published and unpublished sources and included them if they reported outcome data of interest. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data, assessed trial quality and checked decisions within the group. Data extraction included combined cardiovascular events (major adverse cardiac event, @entity177 ); mortality; @entity583 ( @entity583 ); @entity75 revascularisation (TLR); target vessel revascularisation (TVR) and @entity715 . Data synthesis included meta-analysis of combined cardiovascular events, mortality, @entity583 and revascularisation rates, presented as odds ratios with 95% confidence intervals (CI) using a fixed-effect model. We assessed heterogeneity between trials. MAIN RESULTS: The update of the review included 24 new trials (13,391 @entity1 ) resulting in a total of 71 trials (28,713 @entity1 ). In the main there were no statistically significant differences in mortality, @entity583 or @entity715 between DES and BMS, (the exceptions were @entity3446 reporting significant differences in @entity583 at two and three years and Everolimus DES @entity715 rates at one year. These benefits were not evident at four or five years). For composite events, TLR and TVR reductions were evident with use of @entity3446 , @entity1311 , @entity619 , @entity17650 and (to a limited extent) @entity41976 , @entity2239 and unspecified-eluting stents e.g. @entity3446 composite events at five years (OR 0.49; 95% CI 0.40 to 0.61). These effects are demonstrated in the longer term follow up. Subgroup analyses (e.g. diabetics) largely mirrored these findings. AUTHORS' CONCLUSIONS: Drug-eluting stents releasing @entity3446 , @entity1311 , @entity619 and @entity17650 reduce composite @entity299 . However, this reduction is due largely to reductions in repeat revascularisation rates as there is no evidence of a significant effect on rates of mortality, @entity583 or @entity715 .

WITHDRAWN: Drug-eluting stents versus bare metal stents for @entity951 or XXXX .

@entity1 :: ('9606', 'Species') :: ['participants', 'Participants'] @entity1187 :: ('MESH:D054058', 'Disease') :: ['ACS', 'acute coronary syndrome'] @entity17650 :: ('MESH:C489443', 'Chemical') :: ['zotarolimus'] @entity75 :: ('MESH:D001927', 'Disease') :: ['target lesion'] @entity41976 :: ('MESH:C518022', 'Chemical') :: ['biolimus A9'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity256 :: ('MESH:D023903', 'Disease') :: ['Restenosis'] @entity177 :: ('MESH:D051437', 'Disease') :: ['target vessel failure'] @entity1459 :: ('MESH:D000789', 'Disease') :: ['unstable angina'] @entity3446 :: ('MESH:D020123', 'Chemical') :: ['sirolimus'] @entity951 :: ('MESH:D000787', 'Disease') :: ['angina'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity2239 :: ('MESH:C107135', 'Chemical') :: ['everolimus'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events'] @entity583 :: ('MESH:D009203', 'Disease') :: ['AMI', 'acute myocardial infarction'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']
@entity1187 :: (MESH:D054058,Disease) :: ['acute coronary syndromes']
